MOTS-c versus CB4211: the molecule and its analog, side by side
Every row cites its source. Where a cell reflects our own reading of the evidence rather than an external source, the row says so.
When someone says MOTS-c has been through human trials, they are usually thinking of CB4211. These are two different substances with two different evidence files, and FDA classifies even the free base and acetate salt of MOTS-c as distinct.
| Attribute | MOTS-c (what is sold) | CB4211 (what was trialed) | Source |
|---|---|---|---|
| What it is | The natural 16-amino-acid mitochondrial peptide, made synthetically | An analog developed from licensed MOTS-c intellectual property | source |
| Human trials run | 1 registered (Phase 2a, recruiting since Feb 2026) | 1 completed (Phase 1a/1b, 88 participants, ended April 2021) | source |
| Results published | None; the registered trial has posted nothing | None; no results posted and zero PubMed records for CB4211 | source |
| Named in the trial record | Yes, intervention listed as MOTS-c (MDP) | No; the registry record never mentions MOTS-c | source |
| Sold to consumers | Yes, as research-use vials | No | source |
| FDA status | Not approved; proposed for exclusion from the 503A list; no human exposure data identified | Investigational; never approved | source |